Insights

Strategic pivot bioSyntagma halted active operations as of May 2023, indicating a potential need for legacy product support, partner engagement, or acquisition conversations to leverage their remaining technology assets and intellectual property.

Molecular Fingerprint Their core mPrint platform offers multi-omic and spatial tumor profiling, presenting a sales opportunity for biopharma and diagnostics companies seeking precision medicine capabilities, companion diagnostics, or patient screening tools.

COVID collaboration Historical partnerships with Prorenata Labs, Takara Bio USA, and P2 Diagnostics around high-throughput and rapid COVID-19 testing suggest a track record of scalable diagnostic collaborations that could be reactivated or repurposed with interested partners.

Funding and growth Revenue and modest funding indicate a small-to-mid stage company with potential for strategic investment, licensing deals, or joint ventures to commercialize remaining tech, especially in oncology and diagnostic platforms.

Market positioning Awards for oncology-focused precision medicine and sustainability disruption highlight a credible credibility signal; potential buyers or partners include larger CROs, diagnostics firms, and pharma seeking advanced profiling capabilities.

Similar companies to bioSyntagma

bioSyntagma Tech Stack

bioSyntagma uses 8 technology products and services including WordPress Super Cache, WordPress, MySQL, and more. Explore bioSyntagma's tech stack below.

  • WordPress Super Cache
    Caching
  • Content Management System
  • MySQL
    Database
  • Google Fonts API
    Font Scripts
  • Twemoji
    Font Scripts
  • GoDaddy
    Web Hosting
  • Apache
    Web Servers
  • Nginx
    Web Servers

Media & News

bioSyntagma's Email Address Formats

bioSyntagma uses at least 1 email format:
bioSyntagma Email FormatsExamplePercentage
First@biosyntagma.comJohn@biosyntagma.com
100%

Frequently Asked Questions

What is bioSyntagma's phone number?

Minus sign iconPlus sign icon
You can contact bioSyntagma's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is bioSyntagma's official website and social media links?

Minus sign iconPlus sign icon
bioSyntagma's official website is biosyntagma.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does bioSyntagma generate?

Minus sign iconPlus sign icon
As of September 2026, bioSyntagma's annual revenue is estimated to be $1M - $10M.

What is bioSyntagma's SIC code and NAICS code?

Minus sign iconPlus sign icon
bioSyntagma's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does bioSyntagma have currently?

Minus sign iconPlus sign icon
As of September 2026, bioSyntagma has approximately 2 employees across 1 continents, including North America. Key team members include Co-Founder; Director Of Operations: C. Z. and Principal Scientist: D. N. D. Explore bioSyntagma's employee directory with LeadIQ.

What industry does bioSyntagma belong to?

Minus sign iconPlus sign icon
bioSyntagma operates in the Biotechnology Research industry.

What technology does bioSyntagma use?

Minus sign iconPlus sign icon
bioSyntagma's tech stack includes WordPress Super Cache, WordPress, MySQL, Google Fonts API, Twemoji, GoDaddy, Apache and Nginx.

What is bioSyntagma's email format?

Minus sign iconPlus sign icon
bioSyntagma's email format typically follows the pattern of First@biosyntagma.com. Find more bioSyntagma email formats with LeadIQ.

How much funding has bioSyntagma raised to date?

Minus sign iconPlus sign icon
As of September 2026, bioSyntagma has raised $1.4M in funding. The last funding round occurred on Apr 19, 2018 for $196K.

When was bioSyntagma founded?

Minus sign iconPlus sign icon
bioSyntagma was founded in 2015.
bioSyntagma logo

bioSyntagma

Biotechnology ResearchArizona, United States2-10 Employees

bioSyntagma is a biotechnology research company focused on precision cancer medicine. Its Molecular Fingerprint platform generates a comprehensive, multi-omic and spatial profile of a patient’s tissue to inform therapy choices and help prevent acquired drug resistance, serving clinicians, academic researchers, and drug developers. Based in Phoenix, Arizona, the company aims to advance the implementation of precision oncology by providing deep, patient-specific cancer data to guide treatment decisions. The organization operates with a small team and has pursued partnerships to scale diagnostic capabilities and testing workflows, including collaborations related to COVID-19 testing, illustrating its involvement in diagnostic-scale solutions alongside cancer-focused work.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
2-10

Section iconFunding & Financials

  • $1.4M

    bioSyntagma has raised a total of $1.4M of funding over 4 rounds. Their latest funding round was raised on Apr 19, 2018 in the amount of $196K as a Grant.

  • $1M - $10M

    bioSyntagma's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.